CN105770098A - Blood pressure reducing composition and application thereof - Google Patents
Blood pressure reducing composition and application thereof Download PDFInfo
- Publication number
- CN105770098A CN105770098A CN201610153874.XA CN201610153874A CN105770098A CN 105770098 A CN105770098 A CN 105770098A CN 201610153874 A CN201610153874 A CN 201610153874A CN 105770098 A CN105770098 A CN 105770098A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- composition
- pressure reducing
- blood pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 230000036772 blood pressure Effects 0.000 title claims abstract description 27
- 230000001603 reducing effect Effects 0.000 title claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 52
- 239000000843 powder Substances 0.000 claims abstract description 17
- 240000000560 Citrus x paradisi Species 0.000 claims abstract description 11
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 11
- 230000001077 hypotensive effect Effects 0.000 claims description 35
- 208000001953 Hypotension Diseases 0.000 claims description 33
- 208000021822 hypotensive Diseases 0.000 claims description 33
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 12
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 12
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 claims description 12
- 244000046146 Pueraria lobata Species 0.000 claims description 12
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 12
- 241000219099 Parthenocissus quinquefolia Species 0.000 claims description 11
- 235000020717 hawthorn extract Nutrition 0.000 claims description 11
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 10
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 10
- 230000036541 health Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 101100174180 Caenorhabditis elegans fos-1 gene Proteins 0.000 claims description 3
- 101000905241 Mus musculus Heart- and neural crest derivatives-expressed protein 1 Proteins 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 abstract 1
- 241001018563 Nekemias grossedentata Species 0.000 abstract 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 abstract 1
- 229940107187 fructooligosaccharide Drugs 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000000919 ceramic Substances 0.000 description 4
- -1 extracted Substances 0.000 description 4
- 240000000249 Morus alba Species 0.000 description 3
- 235000008708 Morus alba Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 102100030841 AT-rich interactive domain-containing protein 4A Human genes 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 101000792933 Homo sapiens AT-rich interactive domain-containing protein 4A Proteins 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 2
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- VVVDGSCGBGBGFN-UHFFFAOYSA-O 2-[decoxy(hydroxy)phosphoryl]oxyethyl-trimethylazanium Chemical group CCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C VVVDGSCGBGBGFN-UHFFFAOYSA-O 0.000 description 1
- 241000563984 Ampelopsis Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241001092040 Crataegus Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 240000008892 Helianthus tuberosus Species 0.000 description 1
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a blood pressure reducing composition and application thereof. The blood pressure reducing composition comprises, by weight, 30-50 parts of L-arabinose, 20-40 parts of grapefruit powder, 5-20 parts of radix puerariae extract, 5-15 parts of fructus crataegi extract, 5-15 parts of folium mori extract, 1-10 parts of ampelopsis grossedentata leaf extract, 1-10 parts of radix ginseng extract, 1-10 parts of semen cassiae extract and 1-10 parts of fructooligosaccharide. As proved via animal experiments, the blood pressure reducing composition and the application have the advantages that synergistic pressure reducing effects can be realized by various raw materials in the blood pressure reducing composition, and the blood pressures of users can be effectively reduced.
Description
Technical field
The present invention relates to a kind of composition and application, particularly relate to a kind of there is hypotensive composition and application.
Background technology
Hypertension is a kind of common disease, frequently-occurring disease, be again the diseases such as coronary heart disease, renal failure, eyeground pathological changes harm because of
Element.Along with the raising of people's living standard, illness rate is in rising trend in recent years, it has also become threaten human health and the weight of life
Want factor, prevent and treat hypertension to have become the Chinese medicine problem of world medicine.Therefore research and development one has blood pressure reduction effect
Health food, while preventing hypertension, reduce patients' blood by dietotherapy, improve the quality of life of people, be to have very much
There is production practices meaning.
Summary of the invention
It is an object of the invention to provide and a kind of there is hypotensive composition.
Second object of the present invention be to provide a kind of have hypotensive composition preparation have blood-pressure reducing health care product or health care food
Application in product.
Third object of the present invention is to provide and comprises a kind of oral formulations with hypotensive composition.
Fourth object of the present invention is to provide and comprises a kind of oral formulations with hypotensive composition and have in preparation hypotensive
Application in health products or health food.
Technical scheme is summarized as follows:
A kind of have hypotensive composition, is made up of following component by weight: Arabinose 30～50 parts, grapefruit powder 20～
40 parts, kudzu root extract 5～20 parts, haw thorn extract 5～15 parts, mulberry-leaf extract 5～15 parts, ampelopsis grossdentata leaf
Extract 1～10 parts, ginseng extract 1～10 parts, cassia seed extract 1～10 parts, FOS 1～10 parts.
Preferred: Arabinose 35 parts, 20 parts of grapefruit powder, kudzu root extract 10 parts, haw thorn extract 10 parts, mulberry leaf
Extract 10 parts, ampelopsis grossdentata leaf extract 5 parts, ginseng extract 3 parts, cassia seed extract 3 parts, FOS 5
Part.
Above-mentioned composition has the application of blood-pressure reducing health care product or health food in preparation.
Comprise the oral formulations of above-mentioned composition.
The formulation of oral formulations is preferred: pulvis, granule, capsule, tablet, water-bindered pill agent, pill or syrup.
Above-mentioned oral formulations has the application of blood-pressure reducing health care product or health food in preparation.
Advantages of the present invention:
Proving through zoopery, in the composition of the present invention, each raw material has Synergistic Hypotensive Effects, it is possible to effectively reduce blood
Pressure.
Detailed description of the invention
Extract is originated:
(1) Arabinose: with the grass fiber such as corncob, maize peel for raw material through dilute acid hydrolysis, decolouring, depickling,
Biofermentation, isolation of purified, crystallize, be dried to obtain.Arabinose is that " Ministry of Public Health is about approval lactobacillus acidophilus in the Ministry of Public Health
Bulletin Deng 7 kinds of new resource foods " (2008 No. 12) new resource food of ratifying.
(2) grapefruit powder: with grapefruit as raw material, extracted, concentrate, the processes such as spray drying forms；Product specification is
10:1.Execution standard is GB/T 29602；
(3) kudzu root extract: with the root of kudzu vine as raw material, is solvent with 70% ethanol, through extracting, concentrate, chromatograph, concentrating,
Be dried, pulverize and sieve, mix, the processes such as packaging forms；Product specification is 10:1.Execution standard is that enterprise puts on record mark
Accurate: Q/610000-G1705881；
(4) haw thorn extract: be broken into meal for raw meal with hawthorn, adds 50% alcohol extract twice (55～60 DEG C), often
Secondary 2 hours, merging filtrate, reclaims ethanol to filtrate without alcohol taste, dilutes with equivalent water, be added on processed good D101 macropore
On polymeric adsorbent, successively with water and the ethanol elution of variable concentrations, collect corresponding eluent, reclaim ethanol, concentrate, spraying
It is dried, to obtain final product.Product specification is 10:1.Execution standard is that enterprise puts on record standard: Q/HSS0040S；
(5) mulberry-leaf extract: with mulberry leaf as raw material, with 70% ethanol as solvent, through extracting, concentrate, chromatograph, concentrating,
Be dried, pulverize and sieve, mix, the processes such as packaging forms；Product specification is 10:1.Execution standard is that enterprise puts on record mark
Accurate: Q/610000-G1705883；
(6) ampelopsis grossdentata leaf extract: with ampelopsis grossdentata leaf as raw material, extracts through water, concentrates, is dried, pulverizes, mistake
The processes such as sieve, packaging form；Product specification is 10:1.Execution standard is that enterprise puts on record standard: Q/610000-G1705899；
(7) ginseng extract: with ginseng as raw material, is solvent with 70% ethanol, through extracting, concentrate, chromatograph, concentrating,
Be dried, pulverize and sieve, mix, the processes such as packaging forms；Product specification is 10:1.Execution standard is that enterprise puts on record mark
Accurate: Q/610000-G1705211；
(8) cassia seed extract: with cassia seed as raw material, extracts through water, concentrates, is dried, pulverizes, sieves, the work such as packaging
Skill processes；Product specification is 10:1.Execution standard is that enterprise puts on record standard: Q/610000-G1705771；
(9) FOS: with jerusalem artichoke extract as raw material, makes through Production by Enzymes.Execution standard is QB/T 2581；
Below in conjunction with specific embodiment, the present invention is further illustrated.
Embodiment 1
A kind of have hypotensive composition, is made up of following component by weight: Arabinose 35 parts, 20 parts of grapefruit powder,
Kudzu root extract 10 parts, haw thorn extract 10 parts, mulberry-leaf extract 10 parts, ampelopsis grossdentata leaf extract 5 parts, ginseng carry
Take thing 3 parts, cassia seed extract 3 parts, FOS 5 parts.
Embodiment 2
Arabinose 30 parts, 40 parts of grapefruit powder, kudzu root extract 5 parts, haw thorn extract 15 parts, mulberry-leaf extract 5 parts,
Ampelopsis grossdentata leaf extract 10 parts, ginseng extract 1 part, cassia seed extract 10 parts, FOS 1 part.
Embodiment 3
Arabinose 50 parts, 20 parts of grapefruit powder, kudzu root extract 20 parts, haw thorn extract 5 parts, mulberry-leaf extract 15
Part, ampelopsis grossdentata leaf extract 1 part, ginseng extract 10 parts, cassia seed extract 1 part, FOS 10 parts.
Embodiment 4
A kind of have hypotensive composition and prepare:
Weigh the component of each embodiment, mix.
Embodiment 5
Comprise a kind of granule with hypotensive composition of embodiment 1, be will to there is hypotensive composition plus pharmacy
Acceptable auxiliary material, makes granule according to a conventional method, and this granule can be as solid beverage, convenient use.
Embodiment 2 or embodiment 3 a kind of being had hypotensive composition and substitutes the composition of the present embodiment, other is with this reality
Execute example, prepare corresponding granule.
Embodiment 6
Comprise a kind of capsule with hypotensive composition of embodiment 1, be will to there is hypotensive composition plus pharmacy
Acceptable auxiliary material, makes particle according to a conventional method, particle is loaded capsule.
Embodiment 2 or embodiment 3 a kind of being had hypotensive composition and substitutes the composition of the present embodiment, other is with this reality
Execute example, prepare corresponding capsule.
Embodiment 7
Comprise a kind of tablet with hypotensive composition of embodiment 1, be to add that pharmacy can by having hypotensive composition
The auxiliary material accepted, makes particle according to a conventional method, and tablet made by compressing tablet.
Embodiment 2 or embodiment 3 a kind of being had hypotensive composition and substitutes the composition of the present embodiment, other is with this reality
Execute example, prepare corresponding tablet.
Embodiment 8
Comprise a kind of water-bindered pill agent with hypotensive composition of embodiment 1, be will to there is hypotensive composition plus pharmacy
Acceptable auxiliary material, makes water-bindered pill agent according to a conventional method.
Embodiment 2 or embodiment 3 a kind of being had hypotensive composition and substitutes the composition of the present embodiment, other is with this reality
Execute example, prepare corresponding water-bindered pill agent.
Embodiment 9
Comprise a kind of pill with hypotensive composition of embodiment 1, be will to there is hypotensive composition plus pharmacy
Acceptable auxiliary material, drips according to a conventional method and makes pill.
Embodiment 2 or embodiment 3 a kind of being had hypotensive composition and substitutes the composition of the present embodiment, other is with this reality
Execute example, prepare corresponding pill.
Embodiment 10
Comprise a kind of syrup with hypotensive composition of embodiment 1, be will to there is hypotensive composition plus pharmacy
Acceptable auxiliary material, makes syrup according to a conventional method.
Embodiment 2 or embodiment 3 a kind of being had hypotensive composition and substitutes the composition of the present embodiment, other is with this reality
Execute example, prepare corresponding syrup.
Embodiment 11
Pharmacodynamic experiment:
With the composition of the present invention to Hypertensive Rats gavage, successive administration 14 days, the composition observing the present invention is big to hypertension
The impact of mouse blood pressure level.
1, experiment purpose
Observe and a kind of there is the impact on SHR rat blood pressure level of the hypotensive composition.
2, experiment material
2.1. test specimen
2.2.1 test medicine
Title: a kind of have hypotensive composition (embodiment 1, embodiment 2 and embodiment 3)
Proterties: brown solid powder
Compound method: be configured to the concentration suspension as 10mg/ml with water.
2.1.2 positive drug
2.1.2.1
Title: kudzu root extract
Proterties: off-white powder
Produce: Shanxi Jiahe Plant Chemical Co., Ltd.
Compound method: be configured to the concentration suspension as 10mg/ml with water.
2.1.2.2
Title: haw thorn extract
Proterties: brown ceramic powder
Produce: Shanxi Jiahe Plant Chemical Co., Ltd.
Compound method: be configured to the concentration suspension as 10mg/ml with water.
2.1.2.3
Title: mulberry-leaf extract
Proterties: brown ceramic powder
Produce: Shanxi Jiahe Plant Chemical Co., Ltd.
Compound method: be configured to the concentration suspension as 10mg/ml with water.
2.1.2.4
Title: ampelopsis grossdentata leaf extract
Proterties: blackish green powder
Produce: Shanxi Jiahe Plant Chemical Co., Ltd.
Compound method: be configured to the concentration suspension as 10mg/ml with water.
2.1.2.5
Title: ginseng extract
Proterties: brown ceramic powder
Produce: Shanxi Jiahe Plant Chemical Co., Ltd.
Compound method: be configured to the concentration suspension as 10mg/ml with water.
2.1.2.6
Title: cassia seed extract
Proterties: brown ceramic powder
Produce: Shanxi Jiahe Plant Chemical Co., Ltd.
Compound method: be configured to the concentration suspension as 10mg/ml with water.
2.1.3 animal used as test
Essential hypertension rat model (SHR).50, male, 10 week old, body weight 180～220g, shrink pressure > 180mmHg,
Buy in Beijing Vital River Experimental Animals Technology Co., Ltd. (quality certification number: CXK (capital) 2008-0005, meet one-level experiment
Minimal standards).Every 5, cage nursing, freely intakes, environment temperature (25 ± 1) DEG C, relative humidity (60 ± 5) %.SHR
Rat adaptation environment, after 7 days, starts test.
2.1.4 laboratory apparatus
RBP-1 rat blood pressure meter, Beijing large hunting park Science and Technology Ltd.；
SL-1001 type electronic balance, Minqiao Precision Scientific Instruments Co., Ltd., Shanghai.
3. experimental technique
3.1SHR rat is grouped
After 50 SHR rats adapt to environment, measure blood pressure with RBP-1 type rat blood pressure meter, according to blood pressure level by SHR rat
Being randomly divided into 10 groups, respectively blank group, embodiment 1 composition group, embodiment 2 composition group, embodiment 3 combines
Thing group and positive drug control group are (respectively with haw thorn extract group, kudzu root extract group, ampelopsis grossdentata leaf extract group, mulberry
Leaf extract group, ginseng extract group, cassia seed extract group) suspension oral gavage.
3.2 medication
5 SHR rats of blank group, give the distilled water of corresponding dosage；
Other organizes suspension oral gavage.
3.3 methods of administration: oral administration gavage is administered.
3.4 administering modes and dosage:
Positive drug control group and a kind of have hypotensive composition group all with 0.1ml/10g body weight be administered.
Successive administration 14 days, when measuring 2h after gavage respectively when the 0th, 2,4,6,8,10,12 and 14 days, SHR is big
The blood pressure of mouse.
3.5SHR rat blood pressure assay method
The mensuration of animal blood pressure is clear-headed animal, carry out under rest state, rat-tail set is positioned over rat-tail root, between measuring every time
Every certain time, continuous three to five readings of recorded heart rate change≤10 times/min, blood pressure≤6mmHg, take it average
Value.
4. experimental result
A kind of compared with blank group have hypotensive composition group and positive drug has notable hypotensive activity.
Table 1 SHR test each sky blood pressure (mmHg)
Comparing with 0 day analog value of SHR rat, * represents P ＜ 0.05；* represents P ＜ 0.01；
Result shows: compare with 0 day analog value of SHR rat, embodiments of the invention 1, embodiment 2, the combination of embodiment 3
Thing suspension and positive contrast's medicine haw thorn extract, mulberry-leaf extract, ginseng extract, cassia seed extract, the root of kudzu vine carry
Take thing, ampelopsis grossdentata leaf extract (data shows: Arabinose, FOS, grapefruit powder do not have blood pressure reduction effect)
All can reduce the blood pressure of SHR rat after treatment, its drop in blood pressure rate is respectively 13.37%, 6.90%, 7.38%, 3.95%, 3.91%,
2.84%, 2.84%, 1.71%, 3.91%, embodiments of the invention 1 composition has pole significant difference, embodiment 2, enforcement
Example 3 composition all has significant difference with positive contrast's medicine ratio respectively.
Proving through above-mentioned test, above medicinal material compounds Synergistic, has good aided blood pressure-lowering effect.
Claims (6)
1. there is a hypotensive composition, it is characterized in that being made up of following component by weight:
Arabinose 30～50 parts, grapefruit powder 20～40 parts, kudzu root extract 5～20 parts, haw thorn extract 5～15
Part, mulberry-leaf extract 5～15 parts, ampelopsis grossdentata leaf extract 1～10 parts, ginseng extract 1～10 parts, cassia seed carry
Take thing 1～10 parts, FOS 1～10 parts.
Composition the most according to claim 1, is characterized in that described Arabinose 35 parts, 20 parts of grapefruit powder, the root of kudzu vine extract
Thing 10 parts, haw thorn extract 10 parts, mulberry-leaf extract 10 parts, ampelopsis grossdentata leaf extract 5 parts, ginseng extract 3 parts,
Cassia seed extract 3 parts, FOS 5 parts.
3. the composition of claim 1 or 2 has the application of blood-pressure reducing health care product or health food in preparation.
4. comprise the oral formulations of claim 1 or 2 composition.
Oral formulations the most according to claim 4, is characterized in that the formulation of described preparation is pulvis, granule, capsule, sheet
Agent, water-bindered pill agent, pill or syrup.
6. oral formulations described in claim 4 or 5 has the application of blood-pressure reducing health care product or health food in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610153874.XA CN105770098A (en) | 2016-03-17 | 2016-03-17 | Blood pressure reducing composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610153874.XA CN105770098A (en) | 2016-03-17 | 2016-03-17 | Blood pressure reducing composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105770098A true CN105770098A (en) | 2016-07-20 |
Family
ID=56393852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610153874.XA Pending CN105770098A (en) | 2016-03-17 | 2016-03-17 | Blood pressure reducing composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105770098A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108552533A (en) * | 2018-03-20 | 2018-09-21 | 硒多宝饮品集团股份有限公司 | A kind of composite plant original drink and preparation method thereof |
| CN112913993A (en) * | 2021-03-01 | 2021-06-08 | 天津市圭谷科技发展股份有限公司 | Compound beverage of compound L-arabinose and syrup and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709165A (en) * | 2005-06-23 | 2005-12-21 | 亥比布勒·哈迪尔 | Fat-regulating and pressure-stabilizing health-care tea and preparation method thereof |
| CN101401601A (en) * | 2006-10-18 | 2009-04-08 | 吴建生 | Five-leaf tea for reducing blood pressure, blood fat and blood sugar |
| CN104857289A (en) * | 2015-05-18 | 2015-08-26 | 彭婷婷 | Ginseng preparation for reducing blood glucose and blood pressure and preparation method of ginseng preparation |
| CN105146655A (en) * | 2015-09-07 | 2015-12-16 | 王保红 | Drink composition containing tea flower as well as preparation method and application of drink composition |
| CN105477618A (en) * | 2016-01-05 | 2016-04-13 | 广州市澳键丰泽生物科技有限公司 | Compound ampelopsis grossedentata blood-pressure-lowering tea and preparation method thereof |
-
2016
- 2016-03-17 CN CN201610153874.XA patent/CN105770098A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709165A (en) * | 2005-06-23 | 2005-12-21 | 亥比布勒·哈迪尔 | Fat-regulating and pressure-stabilizing health-care tea and preparation method thereof |
| CN101401601A (en) * | 2006-10-18 | 2009-04-08 | 吴建生 | Five-leaf tea for reducing blood pressure, blood fat and blood sugar |
| CN104857289A (en) * | 2015-05-18 | 2015-08-26 | 彭婷婷 | Ginseng preparation for reducing blood glucose and blood pressure and preparation method of ginseng preparation |
| CN105146655A (en) * | 2015-09-07 | 2015-12-16 | 王保红 | Drink composition containing tea flower as well as preparation method and application of drink composition |
| CN105477618A (en) * | 2016-01-05 | 2016-04-13 | 广州市澳键丰泽生物科技有限公司 | Compound ampelopsis grossedentata blood-pressure-lowering tea and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 范青生: "《老年进补与食品保健》", 31 January 2002, 江西科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108552533A (en) * | 2018-03-20 | 2018-09-21 | 硒多宝饮品集团股份有限公司 | A kind of composite plant original drink and preparation method thereof |
| CN112913993A (en) * | 2021-03-01 | 2021-06-08 | 天津市圭谷科技发展股份有限公司 | Compound beverage of compound L-arabinose and syrup and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105832794A (en) | Application of Gynura procumbens to production of medicine, healthcare food or functional food for preventing and treating hyperuricemia | |
| CN104000197B (en) | A kind of health products or pharmaceutical composition and its production and use of fatigue-relieving | |
| CN102258680B (en) | Chinese medicinal composition for reliving physical fatigue and preparation method and use thereof | |
| CN101664180A (en) | Health-care nutritional complexing agent with effect of and preparation method thereof | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN105770098A (en) | Blood pressure reducing composition and application thereof | |
| CN103830301A (en) | Flos chrysanthemi with liver tonifying function and application thereof | |
| CN106177433A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati | |
| US20050163874A1 (en) | Data analysis method | |
| CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
| CN101934044B (en) | Novel application of ginseng, tuckahoe and atractylodes preparation | |
| WO2019100843A1 (en) | Enteromorpha prolifera polysaccharide composite blood lipid-lowering health care product and preparation method therefor | |
| CN103830280A (en) | Preparation method of spirulina extract | |
| CN104435072B (en) | A kind of extract and preparation method thereof with auxiliary hyperglycemic, reducing blood lipid | |
| CN108904596B (en) | Composition with memory improving effect | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN102225082B (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof | |
| CN113499366A (en) | Composition with function of reducing blood sugar and blood fat simultaneously and preparation method thereof | |
| JP7523889B2 (en) | Pharmaceutical composition for improving activity level | |
| CN106177476A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Pericarpium Citri Reticulatae | |
| CN101322762B (en) | Medicinal composition for treating diabetes | |
| CN107137621A (en) | It is a kind of to treat Chinese medicine composition of high fat of blood and its preparation method and application | |
| CN102327304A (en) | Drug for preventing and controlling chronic mountain sickness and preparation method thereof | |
| CN107997170A (en) | A kind of composition with hypolipemic function and preparation method thereof | |
| CN107692196A (en) | It is a kind of that there are health products for removing vivotoxin function and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160720 |